



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the use of Alemtuzumab in Chronic Lymphocytic Leukemia (CLL)
Capital District Health Authority/*Cancer Care Nova Scotia***

Approved Use:

Alemtuzumab: As a single agent in patients (excluding those with bulky adenopathy) with progressive and symptomatic CLL who are refractory to both alkylator-based and fludarabine-based regimens.

- This policy recommendation represents a **new guideline document** and an **addition** to the list of restricted drugs for the use of alemtuzumab in CLL.